Neuroendocrine Carcinoma

Updated: July 15, 2022

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

everolimus

Orally

once a day

the total duration of therapy is continued until disease progression, or no toxicity occurs
Note:
Tablets need to be swallowed with a glass of water but do not chew, crush, or break the tablet
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them

copper CU 64 dotatate

Indicated for Neuroendocrine Tumors
148 MBq (4 mCi) intravenous bolus for nearly 1 min
Note:
Before administering the therapy, it is key to assess the pregnancy condition in females of reproductive potential

lutetium lu 177-dota-tate

Indicated for gastroenteropancreatic neuroendocrine tumors that are somatostatin receptor-positive
7.4GBq intravenously every 8 weeks for a sum of 4 doses administered simultaneously with other concomitant medications and pre-medications
Premedication & concomitant medications include; somatostatin analogs, antiemetics, amino acid solution

Future Trends